Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies…
4basebio AG is working on developing a faster and more sensitive test for SARS-CoV-2 infection with the funds from the Carlos III Health Institute (Instituto de Salud Carlos III) that belongs to the Spanish Ministry of Science and Innovation.
Field reps can compliantly create sample orders and fulfill requests from healthcare professionals during remote meetings Rapid pace of Veeva…
BOSTON–(BUSINESS WIRE)–#ADHD—Akili today announced that ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD)…
Actinium expects to raise $27.5 million to invest in its Sierra phase 3 trial, as well as other programs with…
PrecisionLife is extending its relationships with some of the largest COVID-19 collaborative research projects as it offers free use of its analytics platform and support from its data and biomedical science teams in the fight against COVID19 coronavirus.
Hemogenyx Pharmaceuticals got European Patent Office’s patent entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use.
Applied DNA Sciences has signed an Agreement with Stony Brook University Hospital (the “Hospital”) to validate and implement the Company’s patent-pending nucleic acid diagnostic (LineaCOVID-19™) to detect and quantify in diagnostic samples the presence of SARS-CoV-2, the virus that causes the disease, COVID-19.
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.
Roche said Monday that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and the European Medicines Agency (EMA) has validated the application for a two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly for relapsing or primary progressive multiple sclerosis (MS).